TAK‐659, AN INVESTIGATIONAL REVERSIBLE DUAL SYK/FLT‐3 INHIBITOR, IN PATIENTS WITH LYMPHOMA: UPDATED RESULTS FROM DOSE‐ESCALATION AND EXPANSION COHORTS OF a PHASE 1 STUDY. (June 2017) - Kaplan, J.; Gordon, L.; Infante, J.; Popat, R.; Rambaldi, A.; Madan, S.; Patel, M.R.; Gritti, G.; El‐Sharkawi, D.; Chau, I.; Radford, J.; Perez De Oteyza, J.; et al.